Cytek Biosciences (CTKB) risk factors, FY2024 10-K

Other

1. 01These stockholders, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transaction

Risks Related to Our Business and Strategy

1. 02We have a limited operating history and only recently launched our commercial products, which may make it difficult to evaluate the prospects for our future viability and predict our future performance. We have limited experience marketing and selling our products
2. 03We are highly dependent on a limited number of product offerings. Our revenue has been primarily generated from sales of our core Cytek Aurora, Northern Lights and Aurora CS systems, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue
3. 04Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory
4. 05International operations and expansion of our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States
5. 06We are subject to governmental export controls and sanctions programs that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws
6. 07We have limited experience manufacturing our products, and if we are unable to manufacture our products in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited
7. 08Our future success is dependent upon our ability to increase penetration in our existing markets and expand into adjacent markets
8. 09Our business currently depends significantly on research and development spending by academic and government-owned institutions, a reduction in which could limit demand for our solutions and adversely affect our business and operating results
9. 10We rely on distributors for sales of our products in certain geographies outside of the United States. If we are unable to secure additional distributors or maintain good relationships with our existing distributors, or if such distributors do not perform adequately or effectively, our business could suffer
10. 11The market for cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain profitability
11. 12Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers
12. 13New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all
13. 14Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons, including failure of the product to perform as expected and failure to reliably demonstrate the advantages of the product
14. 15We may acquire other businesses or form other joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense
15. 16Shipping is a critical part of our business and any changes in our shipping arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects
16. 17If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, technical applications specialists and customer support staff, our business may be adversely affected
17. 18If we are unable to expand or leverage the number of peer-reviewed articles published using data generated by our products or otherwise increase brand awareness, the demand for our products and our business may be adversely affected
18. 19We are highly dependent on our senior management team and key personnel and our business could be harmed if we are unable to attract and retain personnel necessary for our success
19. 20We have increased the size of our organization and expect to further increase it in the future, and we may experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed
20. 21We may need to raise additional capital to fund our existing operations, develop our products and/or expand our operations
21. 22Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
22. 23The sizes of the markets for our products may be smaller than we estimate
23. 24If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our existing products and limit commercialization of any products that we may develop
24. 25Litigation and other legal proceedings may harm our business
25. 26service providers) for our data processing–related activities and share or receive Sensitive Information with or from third parties
26. 27Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident
27. 28Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
28. 29Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities
29. 30We are subject to foreign currency exchange risk

Risks Related to Government Regulation and Our Industry

1. 31We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements
2. 32Our products or any component thereof may be subject to product recalls in the future. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us
3. 33The misuse or off-label use of our products may harm our reputation in the marketplace, or result in injuries that lead to product liability suits, which could be costly to our business. Moreover, we could be subject to FDA sanctions if we are deemed to have engaged in off-label promotion
4. 34Changes in tariffs or other government trade policies may materially adversely affect our business and results of operations, including by reducing demand for our products
5. 35in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences
6. 36If we fail to comply with U.S. federal and state fraud and abuse and other healthcare laws and regulations, including those relating to kickbacks and false claims, we could face substantial penalties and our business operations and financial condition could be harmed
7. 37Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business, financial condition and results of operations

Risks Related to Our Intellectual Property

1. 38Patents covering our current, and any future products, or our technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, which could harm our business, financial condition and results of operations
2. 39We rely substantially on our trademarks and trade names. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be harmed
3. 40intellectual property, including patent, protection could be reduced or eliminated for non-compliance with these requirements
4. 41We have limited foreign intellectual property rights outside the United States, selected countries in the European Union, Japan and China and may not be able to protect our intellectual property and proprietary rights throughout the world, which could harm our business, financial condition and results of operations
5. 42Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our current and any future products
6. 43time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to file any patent application related to our current and any future products
7. 44Third-party claims of intellectual property infringement, misappropriation or other violation against us, the joint-owners of our intellectual property, or our collaborators may prevent or delay the sale and marketing of our current and any future products
8. 45We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
9. 46If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
10. 47Failure of a key information technology system, process, or site could have an adverse effect on our business
11. 48Our use of open source software could compromise our ability to offer our services and subject us to possible litigation

Risks Related to Ownership of Our Common Stock

1. 49Our stock price may continue to be volatile, and our stockholders may not be able to resell shares of our common stock at or above the price they paid
2. 50We have broad discretion in the use of our cash and may invest or spend the funds in ways with which you do not agree and in ways that may not yield a return
3. 51Substantial future sales of shares of our common stock or securities convertible into our common stock will result in additional dilution of the percentage of ownership of our stockholders and could cause the market price of our common stock to decline
4. 52Concentration of ownership of our common stock among our executive officers, directors and principal stockholders and their respective affiliates may prevent new investors from influencing significant corporate decisions
5. 53We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
6. 54Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
7. 55Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
8. 56We could be subject to securities class action litigation
9. 57We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices
10. 58Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock
11. 59If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, our common stock price and trading volume could decline
12. 60Our ability to use our net operating losses (“NOLs”) to offset future taxable income may be subject to certain limitations
13. 61Changes in our effective tax rate or tax liability may have an adverse effect on our results of operations
14. 62Changes in tax law and regulations may have a material adverse effect on our business, financial condition and results of operations
15. 63Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders